Home » Stocks » CMPI

Checkmate Pharmaceuticals, Inc. (CMPI)

Stock Price: $14.90 USD 0.89 (6.35%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 321.10M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 13.58M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $14.90
Previous Close $14.01
Change ($) 0.89
Change (%) 6.35%
Day's Open 14.14
Day's Range 13.88 - 15.62
Day's Volume 39,818
52-Week Range 8.71 - 17.62

News

GlobeNewsWire - 2 weeks ago

Robert F. Dolski appointed as Chief Financial Officer

About CMPI

Checkmate Pharmaceuticals, a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor's ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Industry
Biotechnology
IPO Date
Aug 7, 2020
CEO
Barry A. Labinger
Employees
21
Stock Exchange
NASDAQ
Ticker Symbol
CMPI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for CMPI stock is "Buy." The 12-month stock price forecast is 25.75, which is an increase of 72.82% from the latest price.

Price Target
$25.75
(72.82% upside)
Analyst Consensus: Buy